Stock Yards Bank & Trust Co. Purchases 551 Shares of Pfizer Inc. $PFE

Stock Yards Bank & Trust Co. lifted its position in Pfizer Inc. (NYSE:PFE) by 0.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 93,054 shares of the biopharmaceutical company’s stock after purchasing an additional 551 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Pfizer were worth $2,256,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. HighMark Wealth Management LLC grew its position in Pfizer by 123.7% in the second quarter. HighMark Wealth Management LLC now owns 4,249 shares of the biopharmaceutical company’s stock worth $103,000 after acquiring an additional 2,350 shares in the last quarter. DHJJ Financial Advisors Ltd. increased its stake in Pfizer by 44.7% during the second quarter. DHJJ Financial Advisors Ltd. now owns 1,959 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 605 shares during the last quarter. Abundance Wealth Counselors increased its stake in Pfizer by 21.3% during the second quarter. Abundance Wealth Counselors now owns 37,849 shares of the biopharmaceutical company’s stock worth $917,000 after acquiring an additional 6,649 shares during the last quarter. Hilltop National Bank purchased a new position in shares of Pfizer during the second quarter valued at approximately $518,000. Finally, Triad Wealth Partners LLC purchased a new position in shares of Pfizer during the second quarter valued at approximately $212,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Up 1.1%

Shares of NYSE PFE opened at $27.37 on Friday. The stock has a 50 day moving average price of $24.67 and a 200 day moving average price of $24.15. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market capitalization of $155.59 billion, a price-to-earnings ratio of 14.56, a PEG ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on PFE. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. UBS Group restated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Saturday, September 27th. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Finally, Bank of America boosted their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.